592 related articles for article (PubMed ID: 27079511)
1. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
2. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
[TBL] [Abstract][Full Text] [Related]
3. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
4. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
[TBL] [Abstract][Full Text] [Related]
5. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
[TBL] [Abstract][Full Text] [Related]
6. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
[TBL] [Abstract][Full Text] [Related]
8. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
Berkowitz ST; Groth SL; Gangaputra S; Patel S
JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
[TBL] [Abstract][Full Text] [Related]
9. Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals.
Idris MY; Fitzsimmons WE; Pemu P
Ther Innov Regul Sci; 2024 Jan; 58(1):175-183. PubMed ID: 37872439
[TBL] [Abstract][Full Text] [Related]
10. Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis.
Allison K; Patel DG; Greene L
JAMA Netw Open; 2021 May; 4(5):e218348. PubMed ID: 34003274
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of race/ethnicity in trials leading to anti-rheumatic drug approval for inflammatory arthritis by the US Food and Drug Administration.
Xie Y; Liu Y; Qin Y; Chen X; Xie Q
Int J Rheum Dis; 2023 Dec; 26(12):2489-2497. PubMed ID: 37854006
[TBL] [Abstract][Full Text] [Related]
14. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
Pease AM; Krumholz HM; Downing NS; Aminawung JA; Shah ND; Ross JS
BMJ; 2017 May; 357():j1680. PubMed ID: 28468750
[No Abstract] [Full Text] [Related]
15. Participation in cancer clinical trials: race-, sex-, and age-based disparities.
Murthy VH; Krumholz HM; Gross CP
JAMA; 2004 Jun; 291(22):2720-6. PubMed ID: 15187053
[TBL] [Abstract][Full Text] [Related]
16. Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review.
Tahhan AS; Vaduganathan M; Greene SJ; Alrohaibani A; Raad M; Gafeer M; Mehran R; Fonarow GC; Douglas PS; Bhatt DL; Butler J
JAMA Cardiol; 2020 Jun; 5(6):714-722. PubMed ID: 32211813
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of worldwide clinical trials by gender: An FDA perspective.
Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
[TBL] [Abstract][Full Text] [Related]
18. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.
Loree JM; Anand S; Dasari A; Unger JM; Gothwal A; Ellis LM; Varadhachary G; Kopetz S; Overman MJ; Raghav K
JAMA Oncol; 2019 Oct; 5(10):e191870. PubMed ID: 31415071
[TBL] [Abstract][Full Text] [Related]
19. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
[TBL] [Abstract][Full Text] [Related]
20. Race and Ethnicity Reporting and Enrollment Disparities in Clinical Trials Leading to FDA Approvals for Breast Cancer Between 2010 and 2020.
Nguyen RH; Silva Y; Lu J; Chen Z; Gadi V
Clin Breast Cancer; 2023 Aug; 23(6):591-597. PubMed ID: 37296063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
